| Literature DB >> 24353642 |
Rubina Sabir1, S Faraz Danish Alvi2, Asher Fawwad3.
Abstract
UNLABELLED: Backgroun and Objective: Resistance to multiple antimicrobials is the major cause of debility and death due to infectious diseases around the world. Our objective was to determine the frequency and antimicrobial susceptibility pattern of aerobic microbial isolates in a clinical laboratory.Entities:
Keywords: Antimicrobial susceptibility; Microbial isolates; Multi-drug resistant (MDR)
Year: 2013 PMID: 24353642 PMCID: PMC3809306 DOI: 10.12669/pjms.293.3187
Source DB: PubMed Journal: Pak J Med Sci ISSN: 1681-715X Impact factor: 1.088
Antimicrobial Sensitivity Zone Pattern
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| 1 | Clavulanic acid (AMC) | 30 µg | ≥ 18 mm | 14 - 17 mm | ≤ 13 mm |
| 2 | Piperacillin / Tazobactam (TZP) | 10/100 µg | ≥ 21 mm | 18 - 20 mm | ≤ 17 mm |
| 3 | Cefotaxime (CTX) | 30 µg | ≥ 26 mm | 23 - 25 mm | ≤ 22 mm |
| 4 | Vancomycin (VA) | 30 µg | ≥ 15 mm | ------- | ------- |
| 5 | Aztreonam (ATM) | 30 µg | ≥ 22 mm | 16 - 21 mm | ≤15 mm |
| 6 | Imipenem (IPM) | 10 µg | ≥ 16 mm | 14 - 15 mm | ≤ 13 mm |
| 7 | Meropenem (MEM) | 10 µg | ≥ 16 mm | 14 - 15 mm | ≤ 13 mm |
| 8 | Amikacin (AK) | 30 µg | ≥ 17 mm | 15 - 16 mm | ≤ 14 mm |
| 9 | Gentamicin (CN) | 10 µg | ≥ 15 mm | 13 - 14 mm | ≤ 12 mm |
| 10 | (Nalidixic acid) NA | 30 µg | ≥ 19 mm | 13 - 18 mm | ≤ 12 mm |
| 11 | (Norfloxacin) NOR | 10 µg | ≥ 17 mm | 13 - 16 mm | ≤ 12 mm |
| 12 | Ofloxacin (OFX) | 05 µg | ≥ 16 mm | --------- | ≤ 15 mm |
| 13 | Ciprofloxacin (CIP) | 05 µg | ≥ 21 mm | 13 - 20 mm | ≤ 12 mm |
| 14 | (Chloramphenicol) C | 30 µg | ≥ 18 mm | 13 - 17 mm | ≤ 12 mm |
| 15 | Sulphamethoxazole (SXT) | 25 µg | ≥ 16 mm | 11 - 15 mm | ≤ 10 mm |
| 16 | (Fosfomycin) FOS | 200 µg | ≥ 16 mm | 13 - 15 mm | ≤ 12 mm |
Pattern of microbial isolates in culture specimen
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tissue (99) | 46 (46.46%) | 42 (42.42%) | 37 (37.3%) | 16 (16.1%) | 7 (7.0%) | 5 (5.0%) | 4 (4.0%) | 4 (4.0%) | 2 (2.0%) | 2 (2.0%) | 1 (1.0%) | 1 (1.0%) | 1 (1.0%) | 1 (1.0%) | 1 (1.0%) | ----- | ----- | -- | -- |
| Pus (98) | 36 (36.73%) | 48 (48.98%) | 25 (25.5%) | 7 (7.1%) | 2(2.0%) | 8 (8.1%) | 9 (9.1%) | 2(2.0%) | 1 (0.2 %) | ----- | ----- | ----- | 3 (3.0%) | 5 (5.1%) | 5 (5.1%) | 1 (0.2 %) | ----- | -- | -- |
| Urine (55) | 21 (38.18%) | 6 (10.90%) | 2 (3.6%) | ----- | ----- | 6 (10.9%) | ----- | 2 (3.6%) | ----- | ----- | ----- | 2 (3.6%) | 8 (14.5%) | -- | -- | ||||
| Bone (34) | 13(38.24%) | 16(47.06%) | 13(38.2%) | 5 (14.7%) | 6 (17.6%) | 1 (2.9%) | 1 (2.9%) | ----- | 2 (5.8%) | ----- | ----- | ---- | 3 (8.8%) | 1(2.9%) | ----- | --- | ---- | ||
| Blood (17) | 1 (5.88%) | 1 (5.88%) | 1 (5.8%) | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ---- | ----- | ----- | ----- | ---- | 14 (82.3%) |
| Fluid(6) | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ---- | 6 (100%) |
| Stool (1) | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ---- | ----- | ----- | ----- | 1(1.8%) | ---- |
| Sputum (1) | ----- | ----- | 1(1.8%) | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ---- | ----- | ----- | ----- | ---- | ---- |
| HVS (!) | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ----- | ---- | ----- | ----- | 1(1.82%) | ---- | ---- |
Data presented as frequency and percentage
Frequency of multi-drug resistant (MDR) microbial isolates on culture
|
|
|
|
|---|---|---|
| Escherichia coli | 117 | 40 (34.19%) |
| Staphylococcus aureus | 113 | 13 (11.50%) |
| Pseudomonas aeruginosa | 77 | 17 (22.08%) |
| Klebsiella pneumoniae | 31 | 7 (22.58%) |
| Candida species | 20 | ------ |
| Proteus species | 19 | 6 (31.58%) |
| Acinetobacter species | 9 | 3 (33.33%) |
| Mixed Growth | 9 | ------ |
| Streptococcus species | 9 | ------ |
| Enterobacter species | 7 | 2 (28.57%) |
| Coliform | 6 | 1 (16.67%) |
| Proteus vulgaris | 6 | ------ |
| Candida albicans | 5 | ------ |
| Proteus mirabilis | 4 | ------ |
| Enterococcus species | 2 | 1 (50%) |
| Staphylococcus saprophyticus | 2 | ------ |
| Citrobacter species | 1 | ------ |
Data presented as frequency and percentage